Newborn screening: Current status

Health Affairs

Volumn 26, Issue 2, 2007, Pages 559-566

  Arn, Pamela H ^a  

^a NEMOURS CHILDREN S CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COST BENEFIT ANALYSIS; FEMALE; GENETIC DISORDER; GENETIC SCREENING; HEALTH CARE POLICY; HEALTH CARE QUALITY; HUMAN; INBORN ERROR OF METABOLISM; INFANT WELFARE; MALE; MANAGEMENT; NEWBORN; NEWBORN SCREENING; ORGANIZATION AND MANAGEMENT; PRIMARY PREVENTION; RISK ASSESSMENT; UNITED STATES;

COST-BENEFIT ANALYSIS; FEMALE; GENETIC DISEASES, INBORN; GENETIC SCREENING; HEALTH POLICY; HUMANS; INFANT WELFARE; INFANT, NEWBORN; MALE; METABOLISM, INBORN ERRORS; NEONATAL SCREENING; POLICY MAKING; PRIMARY PREVENTION; PROGRAM EVALUATION; RISK ASSESSMENT; UNITED STATES;

EID: 33947326873     PISSN: 02782715     EISSN: 02782715     Source Type: Journal    
DOI: 10.1377/hlthaff.26.2.559     Document Type: Article

References (27)

1. D. Marsden, C. Larson, and H.L. Levy, "Newborn Screening for Metabolic Disorders," Journal of Pediatrics 148, no. 5 (2006): 577-584.
2. L. Sweetman, "Newborn Screening by Tandem Mass Spectrometry: Gaining Experience," Clinical Chemistry 47, no. 11 (2001): 1937-1938.
3. D.S. Millington et al., "Tandem Mass Spectrometry: A New Method for Acylcarnitine Profiling with Potential for Neonatal Screening for Inborn Errors of Metabolism," Journal of Inherited Metabolic Disease 13, no. 3 (1990): 321-324.
4. D.S. Millington et al., "The Analysis of Diagnostic Markers of Genetic Disorders to Human Blood and Urine Using Tandem Mass Spectrometry with Liquid Secondary Ion Mass Spectrometry," International Journal of Mass Spectrometry and Ion Processes 111 (1991): 211-228;
5. and E.W. Naylor and D.H. Chace, "Automated Tandem Mass Spectrometry for Mass Newborn Screening for Disorders in Fatty Acid, Organic Acid, and Amino Acid Metabolism," Journal of Child Neurology 14, no. 1 Supp. (1999): S4-S8.
6. B. Wilcken et al., "Screening Newborns for Inborn Errors of Metabolism by Tandem Mass Spectrometry," New England Journal of Medicine 348, no. 23 (2003): 2304-2312.
7. J.M. Wilson and G. Jungner, "Principles and Practice of Screening for Disease," Public Health Paper no. 34 (Geneva: World Health Organization, 1968).
8. "Serving the Family from Birth to the Medical Home: A Report from the Newborn Screening Task Force Convened in Washington, D.C., 10-11 May 1999," Pediatrics 106, no. 2, Part 2 (2000): 383-327.
9. M.S. Watson et al., "Newborn Screening: Toward a Uniform Screening Panel and System," Genetics in Medicine 8, Supp. 1 (2006): 1S-53S.
10. National Newborn Screening and Genetics Resource Center, "National Newborn Screening Status Report," 2 November 2006, http://genes-r-us. uthscsa.edu (accessed 2 January 2007).
11. J.M. Saudubray et al., "Clinical Approach to Inherited Metabolic Disorders in Neonates: An Overview," Seminars in Neonatalogy 7, no. 1 (2002): 3-15.
12. T.G. Derks et al., "The Natural History of Medium-Chain Acyl CoA Dehydrogenase Deficiency in the Netherlands: Clinical Presentation and Outcome," Journal of Pediatrics 148, no. 5 (2006): 665-670.
13. C.J. Wilson et al., "Outcome of Medium-Chain Acyl-CoA Dehydrogenase Deficiency after Diagnosis," Archives of Disease in Childhood 80, no. 5 (1999): 459-462;
14. and R.R. Howell, "We Need Expanded Newborn Screening," Pediatrics 117, no. 5 (2006): 1800-1805.
15. R.D. Steiner, "Evidence Based Medicine in Inborn Errors of Metabolism: Is There Any and How to Find It," American Journal of Medical Genetics, Part A 134, no. 2 (2005): 192-197.
16. D. Atkins, J. Siegel, and J. Slutsky, "Making Policy When the Evidence Is in Dispute," Health Affairs 24, no. 1 (2005): 102-113.
17. For more information, go to the National Coordinating Center's home page, http://www.nccrcg.org.
18. A. Pandor et al., "Clinical Effectiveness and Cost-Effectiveness of Neonatal Screening for Inborn Errors of Metabolism using Tandem Mass Spectrometry: A Systematic Review" (Executive Summary), Health Technology Assessment 8, no. 12 (2004): 1-121;
19. L.N. Venditti et al., "Newborn Screening by Tandem Mass Spectrometry for Medium-Chain Acyl-CoA Dehydrogenase Deficiency: A Cost-Effectiveness Analysis," Pediatrics 112, no. 5 (2003): 1005-1015;
20. and A.E. Carroll and S.M. Downs, "Comprehensive Cost-Utility Analysis of Newborn Screening Strategies," Pediatrics 117, no. 5, Part 2 (2006): S287-S295.
21. K. Johnson et al., "Financing State Newborn Screening Programs: Sources and Uses of Funds," Pediatrics 117, no. 5, Part 2 (2006): S270-S279.
22. P. Rinaldo, S. Hahn, and D. Matern, "Clinical Biochemical Genetics in the Twenty-first Century," Acta Paediatrica 93, no. 445 Supp. (2004): 22-26.
23. P. Rinaldo et al., "Making the Case for Objective Performance Metrics in Newborn Screening by Tandem Mass Spectrometry," Mental Retardation and Developmental Disabilities (forthcoming).
24. B.A. Tarini, D.A. Christakis, and H.G. Welch, "State Newborn Screening in the Tandem Mass Spectrometry Era: More Tests, More False-Positive Results," Pediatrics 118, no. 2 (2006): 448-456.
25. S.E. Waisbren et al., "Effect of Expanded Newborn Screening for Biochemical Genetic Disorders on Child Outcomes and Parental Stress," Journal of the American Medical Association 290, no. 19 (2003): 2564-2572.
26. M.H. Gelb et al., "Direct Multiplex Assay of Enzymes in Dried Blood Spots by Tandem Mass Spectrometry for the Newborn Screening of Lysosomal Storage Disorders," Journal of Inherited Metabolic Disease 29, nos. 2-3 (2006): 397-404.
27. J.R. Botkin et al., "Newborn Screening Technology: Proceed with Caution," Pediatrics 117, no. 5 (2006): 1793-1799.